Chapter One

Hematology Collaboration and Licensing Agreements Analysis Report 2023: Access to Deals Signed by the World's Leading Biopharma Companies - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 22, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of hematology deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.
  • Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced.

Microbiome Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 233 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 22, 2023
Biotechnology, Pharmaceutical, Health, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Antibiotics, Risk management, Real estate, Property management, Commercial property, Lease

Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of microbiome deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter microbiome deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in microbiome deal making since 2016.

Respiratory Collaboration and Licensing Agreements Report 2023: Unprecedented Access to Deals Entered into by the Worlds Leading Biopharma Companies - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 22, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.
  • Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced.

Musculoskeletal Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed Since 2016 by the World's Leading Biopharma Companies - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 22, 2023
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Veterinary medicine, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the musculoskeletal deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the musculoskeletal deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of musculoskeletal deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in musculoskeletal deal making since 2016.
  • Chapter 5 provides a comprehensive and detailed review of musculoskeletal deals signed and announced since 2016 where a contract document is available.

Global Gene Therapy Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 22, 2023
Health, Stem Cells, Genetics, Other Science, Science, Biotechnology, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Pharmaceutical industry, Medical device, Risk management, Fine chemical, Property management, Commercial property, Lease

Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals.
  • This report contains a comprehensive listing of 688 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties.

Global Stem Cell Collaboration and Licensing Agreements Analysis Report 2023: Breakdown by Company A-Z, Deal Type, Therapeutic Target and Upfront, Milestone, Royalties Data - ResearchAndMarkets.com

Retrieved on: 
月曜日, 11月 20, 2023
Biotechnology, Health, Stem Cells, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Mobile phone, Veterinary medicine, Risk management, Fine chemical, Property management, Commercial property, Lease

Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of stem cell deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter stem cell deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2016.

Global Biomarker Collaboration and Licensing Partnering Analysis Report 2023: Gain an Understanding and Analysis of How and Why Companies Enter Deals - ResearchAndMarkets.com

Retrieved on: 
金曜日, 11月 17, 2023
Biotechnology, Pharmaceutical, Health, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Chapter Three, Directory, Chapter One, Pharmaceutical industry, Risk management, Real estate, Property management, Commercial property, Lease

Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter biomarker deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.

Global Genomic Collaboration and Licensing Agreements Analysis Report 2023 with Directory of 857 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 11月 17, 2023
Genetics, Science, Health, Research, Record, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Vaccine, Pharmaceutical industry, Risk management, Real estate, Property management, Commercial property, Lease

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of genomic deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter genomic deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2016.

Regenerative Medicine Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 1,651 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 15, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Regenerative medicine, Record, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Chapter Three, Directory, Chapter One, Veterinary medicine, Risk management, Real estate, Property management, Commercial property, Lease

This report contains a comprehensive listing of 1651 regenerative medicine deals announced since 2016 including financial terms where available, including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.

Key Points: 
  • This report contains a comprehensive listing of 1651 regenerative medicine deals announced since 2016 including financial terms where available, including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.
  • Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the regenerative medicine deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of regenerative medicine deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine deals.

Global Viral Vector Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 377 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
水曜日, 11月 15, 2023
Health, Genetics, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Vaccine, Risk management, Commercial property, Lease, Property management

This report contains a comprehensive listing of 377 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties.

Key Points: 
  • This report contains a comprehensive listing of 377 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties.
  • Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of viral vector deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter viral vector deals.